The pooled prevalence of chronic painful neuropathy is 41.22% among individuals with chemotherapy-induced peripheral neuropathy (CIPN).

Patients treated with platinum-based agents and taxanes had the highest prevalence of chronic painful chemotherapy-induced peripheral neuropathy, researchers found.

The European Medicines Agency has recommended three new medicines to treat breast and cervical cancer and ...

La-Urshalar Brock, FNP-BC, CNM, RNFA, spoke about the oncology nurse’s and APP’s roles in managing chemotherapy-induced peripheral neuropathy in patients with breast cancer. To effectively manage ...

However, the mechanism of Io+Chemo superiority remains to be further elucidated. Methods: The study included 128 patients with resectable stage II-III gastric cancer, in which 63 were given ...

A total of 446 patients from 136 oncology centers in Japan with HER2-positive MBC (57.6% hormone receptor positive) and no prior chemotherapy in the metastatic setting were randomly assigned to ...

SHR-1701 plus CAPOX chemotherapy reduced treatment delays and dose reductions compared with placebo plus CAPOX in HER2-negative gastric/GEJ cancer. The bifunctional PD-L1/TGF-β inhibitor SHR-1701, in ...

Kate thanked staff at the Royal Marsden Hospital As she thanked staff and comforted patients at the hospital, the royal also opened about her "really tough" chemotherapy and joked about becoming ...

Trilaciclib significantly reduced chemotherapy-induced myelosuppression in extensive ... inhibitor significantly reduced the incidence of severe neutropenia (SN) and associated complications ...